Trials / Conditions / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

13 registered clinical trials studyying Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969	Florida International University	Phase 1
Terminated	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795	M.D. Anderson Cancer Center	Phase 1
Completed	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105	City of Hope Medical Center	Phase 1
Active Not Recruiting	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leuk NCT04188405	M.D. Anderson Cancer Center	Phase 2
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Completed	Ex Vivo Drug Sensitivity Testing and Mutation Profiling NCT03860376	Florida International University	—
Recruiting	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991	M.D. Anderson Cancer Center	Phase 1
Terminated	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Rela NCT03576547	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984	University of Southern California	Phase 1
Terminated	Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700	Stanford University	Phase 1
Completed	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and C NCT02311998	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295	M.D. Anderson Cancer Center	Phase 2
Completed	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412	Fred Hutchinson Cancer Center	Phase 3